Effects of Cognitive-motor Training on Cognition, Depression and Daily Functioning in Patients With Mild Cognitive Impairment (MCI)

March 8, 2024 updated by: Guillermo Palacios, Universidad de Zaragoza

Effects of Cognitive-motor Training on Cognition, Depression and Daily Functioning in Patients With Mild Cognitive Impairment (MCI): A Randomized Controlled Trial

This randomized controlled trial evaluated the effectiveness of an immersive virtual reality (IVR) application (focused on a daily activity) to train cognitive functions and its impact on depression and the ability to perform activities of daily living (ADL) in patients with mild cognitive impairment (MCI). With a dose of two sessions per week during six weeks, the study showed significant improvements in cognitive functions and reduction in depression, with notable effects in the experimental group. This underscores the potential of IVR as a valuable tool in the management of MCI.

Study Overview

Detailed Description

Background:

The increase in cases of MCI underlines the urgency of finding effective methods to slow its progression. Given the limited effectiveness of current pharmacological options to prevent or treat the early stages of this deterioration, non-pharmacological alternatives are especially relevant.

Aim: The study aimed to evaluate the effectiveness of an immersive virtual reality (IVR) application, focused on an activity of daily living (ADL), to train cognitive functions and its impact on depression and the ability to perform ADL in patients with MCI. IVR is presented as an innovative tool with the potential to offer a promising non-pharmacological approach.

Methods:The researchers implemented a 40-minute-long intervention, twice a week for six weeks (totaling 12 sessions), using the cupboard task (based on IVR). The study included the participation of individuals with MCI, randomly distributed into control (n=12) and experimental (n=14) groups. The majority in the control group were women (75%), with a mean age of 77.67 years, and in the experimental group, women represented 57.14%, with a mean age of 74.86 years. Cognitive functions, depression, and the ability to perform ADLs were assessed. The scales used were: the Spanish version of the Montreal Cognitive Assessment (MoCA-S), the Short Geriatric Depression Scale (SGDS-S) and the Instrumental Activities of Daily Living Scale. (IADL-S), respectively.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Teruel, Spain, 44003
        • University of Zaragoza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 65 or older
  • Community-dwelling, not in nursing homes
  • Physically functional
  • Understanding and voluntary consent
  • Mild Cognitive Impairment (MCI)
  • MoCA score of 19-25

Exclusion Criteria:

  • Clinical dementia diagnosis
  • MoCA ≤ 18 indicating probable dementia
  • Neurological disorders including stroke or TBI in the last year
  • History of mental/psychiatric disorders
  • Substance abuse
  • Difficulty using VR headset and controllers
  • Medical conditions affecting trial participation
  • Visual/hearing impairments
  • Communication difficulties

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
motor stimulation for 12 sessions (20 minutes per session)
20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
Experimental: Experimental group
20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
motor stimulation for 12 sessions (20 minutes per session)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spanish version of the Montreal Cognitive Assessment (MoCA-S)
Time Frame: 6 weeks
Scores in the MoCA-S scale. Higher scores mean a better outcome.
6 weeks
Short Geriatric Depression Scale (SGDS-S)
Time Frame: 6 weeks
Scores in the SGDS scale. Higher scores mean a worse outcome.
6 weeks
Instrumental Activities of Daily Living Scale (IADL-S)
Time Frame: 6 weeks
Scores in the IADL scale. Higher scores mean a better outcome.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Guillermo Palacios, PhD, Universidad de Zaragoza

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 3, 2023

Primary Completion (Actual)

September 14, 2023

Study Completion (Actual)

September 14, 2023

Study Registration Dates

First Submitted

March 1, 2024

First Submitted That Met QC Criteria

March 8, 2024

First Posted (Actual)

March 15, 2024

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 8, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on cognitive training via immersive virtual reality

3
Subscribe